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Spaceflights lead to dysregulation of the immune cell functionality affecting the expression of 
activation markers and cytokines production. Short oxidized multi-walled carbon nanotubes 
functionalized by 1,3-dipolar cycloaddition have been reported to activate immune cells. In this 
Communication we have performed surface markers assays and multiplex ELISA on primary 
monocytes and T cells under microgravity. We have discovered that carbon nanotubes, through their 
immunostimulatory properties, are able to fight spaceflight immune system dysregulations.  
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Gravity is the force of attraction by which terrestrial bodies tend to fall toward the Earth. In space, living 
organisms are confronted with two important factors: microgravity and cosmic radiation. A microgravity 
environment imparts to an object a lower acceleration compared to that produced by Earth at its surface. 
Experiments conducted by American, Russian, and European investigators, in dedicated space missions as 
well as in simulations on Earth, have shown that mammalian cells are sensitive to gravitational changes.
1-8
 
It is well known that the constant influence of weightlessness leads to several modifications of many 
physiological cellular processes, such as proliferation, differentiation, growth, signal transduction, 
cytoskeletal architecture, motility and gene expression.
1-4
 Moreover, immune cells are severely affected by 
microgravity.
5
 T lymphocyte functions were found altered in more than 50% of crew members in space.
6
 A 
severe inhibition of T cell activation in real and simulated microgravity conditions has been extensively 
demonstrated. Hashemi et al. reported a down regulation of CD25 and CD69 cell membrane activation 
markers in T cells after 24 hours of microgravity condition.
7
 These findings were recently confirmed on US 
Astronauts onboard the Space Shuttle.
8
 CD25 and CD69 are important markers in the T Cells mediate 
immune response. CD25 (alpha chain of the IL-2 receptor) is a late activation antigen. Activation mediated 
by the T-cell receptor (TCR) and costimulatory molecules induce an up-regulation of CD25 in T cells 
making them highly sensitive to IL-2. Whereas, CD69, member of the C-type lectin superfamily (Leu-23), 
is one of the earliest cell surface antigens expressed by T cells following activation. 
We reported that functionalized multi-walled carbon nanotubes (f-MWCNTs) lead to an up-regulation of 
CD25 and CD69 markers expression in human primary immune cells, in particular in monocytes.
9
 Very 
recently, through a whole genome wide study we proposed functionalized CNTs (f-CNTs) as 
immunomodulator systems showing their potential as immune activators 
10
. We would like to highlight that 
in contrast to other types of CNTs, different in functionalization and shape investigated in immune cells,
9-12
 
we found that oxidized MWCNTs, further functionalized by 1,3-dipolar cycloaddition, can act as 
immunomodulators.
9
 No data are present in literature regarding the interaction of CNTs and immune cells 
under microgravity conditions. Encouraged by our recent results, we wanted to evaluate the possibility of 
taking advantage of f-CNT immunostimulatory properties against spaceflight dysregulation of immune 
functions.  
The high cost of experiments on board of spacecraft and space station facilities and the limited number of 
doubling experiments do not allow scientists to give continuity to the studies in real microgravity outside 
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Earth. Currently, thanks to different and advanced facilities, it is possible to carry out studies in 
microgravity simulating in part the spaceflight conditions. In this work, a tridimensional clinostat or 
Random Positioning Machine (RPM) was used to simulate microgravity (M; 0xg) to evaluate if f-CNTs are 
able to compensate immune microgravity induced dysregulation. Static control cell cultures were installed 
in the basement of the RPM. 
We first assessed the possible impact of microgravity on the functionalization of CNTs by transmission 
electron microscopy (TEM) and Kaiser test. To assess whether microgravity affect CNT uptake on primary 
human T cells and monocytes, we studied their internalization in microgravity by flow cytometry and 
confocal microscopy. Taking into consideration the results reported on activation markers by Hashemi et 
al.,
7
 we then focused on CD25 expression on monocytes and T cells through peripheral blood mononuclear 
cells (PBMCs) analysis and CD69, both on T cells present on PBMCs and isolated T lymphocytes, T-
helper cells (CD4+) and cytotoxic T cells (CD8+). To gain a larger picture about CNT effect on immune 
microgravity dysregulation, we also performed a multiplex cytokine assay on PBMCs (TNFα, IL6, IL10, 
IL13, IFNγ, IL2) and on isolated T lymphocytes (IFNγ, IL2).  
By screening a series of functionalized carbon nanotubes, we previously obtained the major effect on 
immune activation treating human primary cells with oxidized MWCNTs subsequently functionalized by 
1,3-dipolar cycloaddition of azomethine ylides.
9, 10
 The present study was carried out with the same type of 
nanotubes in terms of functionalization and shape (Fig. S1). Characterization and functionalization methods 
of the MWCNTs has been previously described by our group.
13
 Kawanami et al. focused on the effect of 
microgravity on CNT synthesis,
14
 but no data are reported in the literature about the possible impact of 
microgravity on f-CNTs. We first assessed by TEM and Kaiser test that MWCNTs (OX-MWCNT-NH3
+
) 
were not affected in their functionalization in microgravity. TEM images do not display differences in the 
morphology of the tubes under the microgravity (Fig. 1), while Kaiser test gave approximately the same 
values (within the uncertainty of this type of measurement) in term of amount of ammonium groups before 
(~40 µmol/g) and after (~50 µmol/g) treatment under microgravity. We previously showed a clear uptake 
on monocytes and T cells by the same type of nanotubes.
9
 To make sure that the equivalent internalization 
can be possible under microgravity conditions, we used the same fluorescently labeled nanotubes (Fig. S2). 
As expected, data from flow cytometry showed a dose-dependent uptake of f-CNTs after 24 h. 
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Interestingly, we did not detect significant difference in the internalization at 0xg (Fig. S3A). We 
confirmed our data at 100 µg/ml concentration for both the samples treated in static control or in 
microgravity by confocal microscopy (Fig. S3B). The absence of difference in cell uptake prompted us to 
go ahead in understanding the potential of carbon nanotubes to modulate the immune spaceflight effects. 
Cellular uptake results led us to choose a working concentration of 100 µg/ml of f-CNTs. We fixed the time 
of incubation at 24 h, the best time point to assess a possible immune response on primary human cells as 
used in the space mission and microgravity experiment on activation markers.
7
 
To evaluate the ability of activator MWCNTs to counteract spaceflight immune suppression,
9
 PBMCs were 
left untreated for 24 h or incubated with 100 μg/ml of OX-MWCNT-NH3
+
 in static controls and under 
microgravity conditions. Lipopolysaccharides (LPS) and concanavalin A (ConA), due to their well-known 
activation properties, were used as positive controls for monocytes (CD14+) and T cells (CD3+) 
respectively (Fig. 2). In addition to our previous data obtained in static conditions,
9
 we here tested a 
possible synergic action of f-CNTs in the presence of traditional activators (LPS or ConA + OX-MWCNT-
NH3
+ 
samples). We first performed a functionality assay on CD14+ monocytes focusing on CD25 marker 
(Fig. 2A). f-CNTs
 
led to an increase of CD25 expression on monocytes, both in static controls and under 
microgravity conditions (M). This finding suggests that the ability of OX-MWCNT-NH3
+ 
to
 
act as 
monocyte activators 
9, 10
 is not affected by microgravity conditions. We then evaluated CD25 expression on 
CD3+ T lymphocytes (Fig. 2B). f-CNTs showed a synergic effect with ConA on CD25 expression in static 
controls. In microgravity we noticed a down-regulation of CD25 on ConA activated samples due the 
immune suppression as already reported.
7
 Interestingly, in microgravity, samples treated with f-CNTs 
together with ConA did not show the down-regulation of CD25. Since it was also previously shown a 
down-regulation of CD69 early activation marker during clinorotation in spaceflight,
7
 we decided to 
evaluate CD69 expression on T lymphocytes (Fig. 2C). Our results demonstrate again that f-CNTs have a 
clear synergic effect with ConA in static controls. The nanotubes counteract the down-regulation of CD69 
due to the microgravity conditions. These findings show that the functional effect on T cells of f-CNTs in 
the presence of ConA is not deeply affected by microgravity in comparison to the treatment with only the 
activator. It is well known that the activation of T cells by ConA is inhibited in 0xg condition.
17 
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The action of ConA on T cells is mediated by G protein that induces phospholipase C and then triggers the 
activation cascade of IL2. Patching and capping of ConA receptor are slightly retarded in microgravity. 
This action dramatically reduces IL2 secretion, and consequently the T cell activation.
17
  
To thoroughly evaluate CNT effect on CD69 expression in T cell in absence of other cells present in 
PBMCs, T lymphocytes were isolated and incubated for 24 h with 100 μg/ml of f-MWCNTs alone or in the 
presence of ConA, and compared to untreated control cells, CD4+ and CD8+ subpopulations were 
analyzed by flow cytometry (Fig. 2D and 2E). We confirmed that f-CNTs with ConA in both 
subpopulations are able to contrast the effect of microgravity. Moreover, these results clearly show that f-
CNTs can act on T lymphocytes even in the absence of monocyte interactions.  
The altered immune cell functionalities have been reported in different studies looking also to the cytokine 
production.
8, 15-19
 Crucian et al. showed on Space Shuttle crew members that post-flight monocytes 
significantly reduced their production of IL-6, TNFα, and IL-10.15 This reduction may impact overall 
immunocompetence. More recently, during the flight it has been shown a down-regulation of IFNγ, TNFα, 
IL10, IL4 and IL6 on whole blood sample of crew members after phorbol 12-myristate 13-acetate and 
ionomycin treatment.
8
 The authors showed that a mitogenic stimulation led to a lower production of IFNγ 
and IL10, and to an up-regulation of TNFα and IL2.8 Moreover, the strongly reduced T lymphocyte 
activation under spaceflight conditions has been reported not only for CD25 marker but also for the 
production of IL2 after ConA stimulation.
17
 To further confirm the ability of f-CNTs to act as 
immunomodulator systems and better investigate their interaction with immune cells under microgravity, 
we performed an assay on a wide range of cytokines. The samples were activated with ConA or left 
untreated in the presence of f-CNTs or without them. Figure 3A illustrates the cytokine production by 
multiplex ELISA on PBMCs supernatants. We confirmed the activator action of f-MWCNTs for the 
classical innate cytokines, TNFα and IL6, as previously reported,9, 20 and we found the synergic effect of f-
CNTs with ConA in static controls and under microgravity. Interestingly, in microgravity, also f-CNTs 
alone are able to up-regulate the IL6 production as they do in static controls. For the other investigated 
cytokines (IL10, IL13, IFNγ and IL2) we found that f-CNTs alone did not boost their production but they 
seem to act in concert with ConA potentiating its stimulation both in static controls and in 0xg conditions. 
To better understand the interaction of f-MWCNTs with T lymphocytes, the major population affected by 
microgravity, we assessed the release of two classical adaptive cytokines, IFNγ and IL2, on T isolated cell 
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population (Fig. 3B). Cell functionality was inhibited by microgravity even in the presence of ConA 
stimulation. In static samples treated with ConA and nanotubes we found instead a statistically significant 
production of IFNγ and IL2 versus medium. Our experiments show that the effect of nanotubes appears to 
be particularly linked to an up-stimulation of the molecular effectors involved in IL2 pathway. We assume 
that f-CNTs could promote the patching and capping of ConA receptor. This action, together with IL2 
pathway stimulation, can explain the synergic effect between f-CNTs and ConA in 0xg. 
 These findings, together with the surface marker data, open new perspectives on the capability of carbon 
nanotubes to act as immunomodulators proving this property by fighting immune function dysregulation in 
microgravity conditions, especially for T lymphocytes.  
 
In conclusion, carbon nanotubes had attracted in the last years a huge interest from the scientific 
communities in a wide variety of biomedical applications.
21
 Among other purposes, we and others focused 
on their possible relevance in biomedicine as drug carriers or contrast agents.
12, 13, 22, 23
 
Encouraged by our recent studies on functionalized carbon nanotubes we wanted to confirm the potential of 
specific functionalized carbon nanotubes as immunomodulators.
9, 10
 NASA is working to achieve the goal 
of returning humans to Moon by 2020 and put footprints on Mars by 2024 (www.nasa.gov.html last access 
12/12/2013). Even if this is a dreaming scenario for humanity, the immune system suppression related to 
spaceflight should be considered more thoroughly before taking in consideration long space voyages. In 
this context nanotechnology may bring additional help for the future of humans on space missions.
24
 Based 
on the results of this study together with further future possible investigations, we can envision an immune 
system pretreatment of space crew members with functionalized CNTs administered intravenously, once all 
issues about clinical applications of nanotubes are solved. We aim at reinforcing the concept that 
functionalized carbon nanotubes are able to stimulate immune cells having very interesting broad future 
applications in immunotherapy, as vaccine adjuvants and, with data here shown, as possible fighter to 
contrast spaceflight immune cells dysregulation. 
 
Electronic supplementary information (ESI) available: Experimental section, structures of f-MWCNTs 
and uptake by human primary immune cells. See DOI: 
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Figure 1. TEM images of OX-MWCNT-NH3
+
 before (A) and after microgravity treatment (B). 
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Figure 2. Activation marker assay. Microgravity (M) was compared with static controls. Peripheral blood 
mononuclear cells and isolated human T lymphocytes were left untreated (medium) for 24 h or incubated 
with 100 μg/ml OX-MWCNT-NH3
+
 alone or in the presence of cell activators (LPS or ConA).  (A) 
Monocytes: CD25 expression was assessed by flow cytometry on CD14+ monocytes present on PBMCs. 
LPS (2 μg/ml) was used as positive control. (B and C) T cells: CD25 (B) and CD69 (C) expression was 
assessed by flow cytometry on CD3+ T cells present on PBMCs. ConA (10 μg/ml) was used as positive 
control. (D and E) Isolated T lymphocytes from PBMCs: staining for CD4+ (D) was performed to identify 
T-helper cell on isolated T lymphocytes; staining of CD8+ (E) was performed to identify cytotoxic T cells. 
Difference in statistical significance (Student’s t-test) is indicated by * = p < 0.05 and ** = p<0.01. Bars 
indicate the compared samples under the different conditions; No-asterisk marked samples are compared to 
controls (medium). 
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Figure 3. Cytokines secretion assay. Cytokine production was assessed by multiplex ELISA on PBMCs 
(A) and on isolated human T lymphocytes (B). Microgravity (M) were compared with static controls. 
Peripheral blood mononuclear cells and isolated T cells were left untreated (medium) for 24 h or incubated 
with 100 μg/ml MWCNTs, alone or in addition with 10 μg/ml ConA. Values are expressed in pg/ml. The 
statistical significance of differences between the samples versus medium controls was calculated by 
Student’s t-test (*, p<0.05).  
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